vs
Side-by-side financial comparison of RLI CORP (RLI) and Bio-Techne (TECH). Click either name above to swap in a different company.
RLI CORP is the larger business by last-quarter revenue ($465.7M vs $311.4M, roughly 1.5× Bio-Techne). RLI CORP runs the higher net margin — 19.6% vs 16.4%, a 3.2% gap on every dollar of revenue. On growth, RLI CORP posted the faster year-over-year revenue change (6.1% vs -1.5%). Over the past eight quarters, RLI CORP's revenue compounded faster (2.3% CAGR vs 1.3%).
RLI Corp. is an American insurance company specializing in property insurance and casualty insurance. It is headquartered in Peoria, Illinois.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
RLI vs TECH — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $465.7M | $311.4M |
| Net Profit | $91.2M | $51.0M |
| Gross Margin | — | 66.9% |
| Operating Margin | 24.4% | 24.2% |
| Net Margin | 19.6% | 16.4% |
| Revenue YoY | 6.1% | -1.5% |
| Net Profit YoY | 123.1% | 126.0% |
| EPS (diluted) | $1.00 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $311.4M | ||
| Q4 25 | $465.7M | $295.9M | ||
| Q3 25 | $509.3M | — | ||
| Q2 25 | $499.8M | $317.0M | ||
| Q1 25 | $407.7M | $316.2M | ||
| Q4 24 | $439.1M | $297.0M | ||
| Q3 24 | $470.0M | $289.5M | ||
| Q2 24 | $416.4M | $306.1M |
| Q1 26 | — | $51.0M | ||
| Q4 25 | $91.2M | $38.0M | ||
| Q3 25 | $124.6M | — | ||
| Q2 25 | $124.3M | $-17.7M | ||
| Q1 25 | $63.2M | $22.6M | ||
| Q4 24 | $40.9M | $34.9M | ||
| Q3 24 | $95.0M | $33.6M | ||
| Q2 24 | $82.0M | $40.6M |
| Q1 26 | — | 66.9% | ||
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 62.7% | ||
| Q1 25 | — | 67.9% | ||
| Q4 24 | — | 65.3% | ||
| Q3 24 | — | 63.2% | ||
| Q2 24 | — | 66.4% |
| Q1 26 | — | 24.2% | ||
| Q4 25 | 24.4% | 18.4% | ||
| Q3 25 | 30.9% | — | ||
| Q2 25 | 31.3% | -7.5% | ||
| Q1 25 | 19.3% | 12.2% | ||
| Q4 24 | 10.8% | 16.0% | ||
| Q3 24 | 24.9% | 13.8% | ||
| Q2 24 | 24.8% | 15.0% |
| Q1 26 | — | 16.4% | ||
| Q4 25 | 19.6% | 12.8% | ||
| Q3 25 | 24.5% | — | ||
| Q2 25 | 24.9% | -5.6% | ||
| Q1 25 | 15.5% | 7.1% | ||
| Q4 24 | 9.3% | 11.7% | ||
| Q3 24 | 20.2% | 11.6% | ||
| Q2 24 | 19.7% | 13.3% |
| Q1 26 | — | $0.32 | ||
| Q4 25 | $1.00 | $0.24 | ||
| Q3 25 | $1.35 | — | ||
| Q2 25 | $1.34 | $-0.11 | ||
| Q1 25 | $0.68 | $0.14 | ||
| Q4 24 | $-2.87 | $0.22 | ||
| Q3 24 | $2.06 | $0.21 | ||
| Q2 24 | $1.78 | $0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $209.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.8B | $2.1B |
| Total Assets | $6.2B | $2.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $209.8M | ||
| Q4 25 | — | $172.9M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $162.2M | ||
| Q1 25 | — | $140.7M | ||
| Q4 24 | — | $177.5M | ||
| Q3 24 | — | $187.5M | ||
| Q2 24 | — | $152.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | $260.0M | ||
| Q3 25 | $100.0M | — | ||
| Q2 25 | $100.0M | $346.0M | ||
| Q1 25 | $100.0M | $330.0M | ||
| Q4 24 | $100.0M | $300.0M | ||
| Q3 24 | $100.0M | $300.0M | ||
| Q2 24 | $100.0M | $319.0M |
| Q1 26 | — | $2.1B | ||
| Q4 25 | $1.8B | $2.0B | ||
| Q3 25 | $1.9B | — | ||
| Q2 25 | $1.7B | $1.9B | ||
| Q1 25 | $1.6B | $2.0B | ||
| Q4 24 | $1.5B | $2.1B | ||
| Q3 24 | $1.7B | $2.1B | ||
| Q2 24 | $1.6B | $2.1B |
| Q1 26 | — | $2.6B | ||
| Q4 25 | $6.2B | $2.5B | ||
| Q3 25 | $6.2B | — | ||
| Q2 25 | $6.0B | $2.6B | ||
| Q1 25 | $5.7B | $2.6B | ||
| Q4 24 | $5.6B | $2.7B | ||
| Q3 24 | $5.8B | $2.7B | ||
| Q2 24 | $5.5B | $2.7B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.13× | ||
| Q3 25 | 0.05× | — | ||
| Q2 25 | 0.06× | 0.18× | ||
| Q1 25 | 0.06× | 0.16× | ||
| Q4 24 | 0.07× | 0.14× | ||
| Q3 24 | 0.06× | 0.14× | ||
| Q2 24 | 0.06× | 0.15× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $156.8M | — |
| Free Cash FlowOCF − Capex | $155.0M | — |
| FCF MarginFCF / Revenue | 33.3% | — |
| Capex IntensityCapex / Revenue | 0.4% | — |
| Cash ConversionOCF / Net Profit | 1.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | $608.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $156.8M | — | ||
| Q3 25 | $179.2M | — | ||
| Q2 25 | $174.7M | $98.2M | ||
| Q1 25 | $103.5M | $41.1M | ||
| Q4 24 | $128.1M | $84.3M | ||
| Q3 24 | $219.4M | $63.9M | ||
| Q2 24 | $141.8M | $75.5M |
| Q1 26 | — | — | ||
| Q4 25 | $155.0M | — | ||
| Q3 25 | $177.8M | — | ||
| Q2 25 | $173.4M | $93.3M | ||
| Q1 25 | $102.5M | $31.0M | ||
| Q4 24 | $127.6M | $77.5M | ||
| Q3 24 | $219.0M | $54.7M | ||
| Q2 24 | $139.1M | $57.5M |
| Q1 26 | — | — | ||
| Q4 25 | 33.3% | — | ||
| Q3 25 | 34.9% | — | ||
| Q2 25 | 34.7% | 29.4% | ||
| Q1 25 | 25.1% | 9.8% | ||
| Q4 24 | 29.0% | 26.1% | ||
| Q3 24 | 46.6% | 18.9% | ||
| Q2 24 | 33.4% | 18.8% |
| Q1 26 | — | — | ||
| Q4 25 | 0.4% | — | ||
| Q3 25 | 0.3% | — | ||
| Q2 25 | 0.3% | 1.5% | ||
| Q1 25 | 0.3% | 3.2% | ||
| Q4 24 | 0.1% | 2.3% | ||
| Q3 24 | 0.1% | 3.2% | ||
| Q2 24 | 0.7% | 5.9% |
| Q1 26 | — | — | ||
| Q4 25 | 1.72× | — | ||
| Q3 25 | 1.44× | — | ||
| Q2 25 | 1.41× | — | ||
| Q1 25 | 1.64× | 1.82× | ||
| Q4 24 | 3.13× | 2.42× | ||
| Q3 24 | 2.31× | 1.90× | ||
| Q2 24 | 1.73× | 1.86× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
RLI
| Casualty Segment | $246.8M | 53% |
| Property Insurance Segment | $122.5M | 26% |
| Other | $59.3M | 13% |
| Surety Insurance Segment | $37.1M | 8% |
TECH
| Protein Sciences segment revenue | $226.2M | 73% |
| Diagnostics and Spatial Biology segment revenue | $85.6M | 27% |
| Other revenue (1) | $5.4M | 2% |
